1. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis
   Yu-Chen Hsu et al, 2021, European Journal of Clinical Pharmacology CrossRef
2. Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non‐inferiority phase III trial
   Jiuwei Cui et al, 2020, European Journal of Cancer Care CrossRef
3. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
   null null et al, 2021, Cochrane Database of Systematic Reviews CrossRef
4. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis
   Ronald Chow et al, 2019, Critical Reviews in Oncology/Hematology CrossRef
5. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis
   Ronald Chow et al, 2018, Supportive Care in Cancer CrossRef
6. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
   Marko Popovic et al, 2014, Supportive Care in Cancer CrossRef